Valneva seeks authorization for its vaccine in the UK

Even though vaccines are already available against Covid-19, Valneva continues its race to have a serum in its name. The Franco-Austrian laboratory announced on Monday that it had started the gradual submission of its request for authorization of its vaccine candidate to the British health authorities.

The laboratory’s phase 3 trials, intended to prove the real effectiveness of a treatment before it is eventually put on the market, are still ongoing. He hopes “that an initial authorization could be granted to it by the end of 2021” for marketing. In addition, Valneva has already signed a contract with the United Kingdom to deliver this vaccine in the event of a positive test.

The first part of the phase 3 trials is taking place in the United Kingdom, but Valneva began in early August “a complementary trial” in New Zealand, with people over 56 years. The laboratory uses a deactivated virus vaccine, a technology more traditional than those of vaccines currently approved in the European Union: Pfizer-BioNTech and Moderna, which are messenger RNA, and AstraZeneca and Johnson & Johnson, which work by viral vector.